Cortexin

Grade C: Preliminary or limited human evidence

TL;DR: Cortexin has more human trial data than most research peptides, including randomized controlled trials, but the evidence has serious limits. A 2018 multicenter randomized study in chronic cerebral ischemia (189 patients, PMID 30335070) reported a dose-dependent effect but was not placebo-controlled or blinded, and a 2020 randomized comparison in early stroke recovery (40 patients, PMID 33449527) found Cortexin underperforming its comparator Cellex. Every trial is single-country and run by groups with manufacturer or institutional ties, with no independent replication outside Russia. The deterministic rubric proposes grade B because randomized trials exist; the grade is held at C by editorial override to reflect that low-confidence, unreplicated, manufacturer-affiliated evidence base.

Key Takeaways

Grade C: Preliminary or limited human evidence
Not FDA approved: Not approved by the FDA or EMA. It is manufactured by Geropharm and approved and marketed in Russia and other CIS countries.
Compounding: Not an FDA-approved drug. The compounding status of imported research peptides is unsettled and changing; confirm current legality with a licensed pharmacist or physician before any use.

Mechanism

A polypeptide mixture extracted from cattle and pig cerebral cortex, proposed to have neuroprotective activity. Because it is a heterogeneous animal-tissue extract rather than a defined molecule, its active components are not fully characterized.

Evidence

Cortexin has more human trial data than most research peptides, including randomized controlled trials, but the evidence has serious limits. A 2018 multicenter randomized study in chronic cerebral ischemia (189 patients, PMID 30335070) reported a dose-dependent effect but was not placebo-controlled or blinded, and a 2020 randomized comparison in early stroke recovery (40 patients, PMID 33449527) found Cortexin underperforming its comparator Cellex. Every trial is single-country and run by groups with manufacturer or institutional ties, with no independent replication outside Russia. The deterministic rubric proposes grade B because randomized trials exist; the grade is held at C by editorial override to reflect that low-confidence, unreplicated, manufacturer-affiliated evidence base.

Safety and risks

A 2023 Cochrane systematic review that pools Cortexin together with the related cattle-brain neuropeptide mixture Cerebrolysin (PMID 37818733) found no reduction in all-cause death (risk ratio 0.96, 95% CI 0.65 to 1.41; 6 trials, 1,689 participants; moderate-certainty evidence) and a probable increase in non-fatal serious adverse events (risk ratio 2.39, 95% CI 1.10 to 5.23; 3 trials, 1,335 participants; moderate-certainty evidence). Cortexin is a heterogeneous polypeptide mixture from animal neural tissue, so its exact composition and batch consistency cannot be independently verified from outside the manufacturer. Long-term safety data beyond the trial windows is not available in the open literature.

Interactions

No formally characterized drug interactions; it has been used as an add-on to standard stroke therapy in trials. Systematic interaction studies do not exist.

Compounding legality

Not an FDA-approved drug. The compounding status of imported research peptides is unsettled and changing; confirm current legality with a licensed pharmacist or physician before any use.

Sources

Cortexin is Not FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 2, 2026 by PeptideGrids editorial team (independently audited).